Selinexor: meta-analysis of COVID-19 studies

All studies Mortality Ventilation ICU Serious outcomes Recovery Viral clearance RCTs RCT mortality All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−286%

Mortality (1)−286%

Ventilation (1)−39%

ICU admission (1)−11%

Viral clearance (1)21%

RCTs (1)−286%

Late (1)−286%

00.511.5+

← Selinexor
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

c19early.org

October 2026

Selinexor COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Geils (SB RCT)−286%3.86 · 0.89–16.86death10/662/51XPORT-CoV-1001

Late treatment−286%3.86 · 0.89–16.8610/662/51286% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.072

All studies−286%3.86 · 0.89–16.8610/662/51286% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.07200.511.52+

Rotate screen for more detailsIncrease width for more details

← Selinexor
reduces riskSelinexor
increases risk →

c19early.org

October 2026

Selinexor COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Geils (SB RCT)−286%3.86 · 0.89–16.8610/662/51XPORT-CoV-1001

Late treatment−286%3.86 · 0.89–16.8610/662/51286% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.072

All studies−286%3.86 · 0.89–16.8610/662/51286% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.07200.511.52+

Rotate screen for more detailsIncrease width for more details

← Selinexor
reduces riskSelinexor
increases risk →

c19early.org

October 2026

Selinexor COVID-19 mechanical ventilation results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Geils (SB RCT)−39%1.39 · 0.50–3.909/665/51XPORT-CoV-1001

Late treatment−39%1.39 · 0.50–3.909/665/5139% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.54

All studies−39%1.39 · 0.50–3.909/665/5139% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.5400.511.52+

Rotate screen for more detailsIncrease width for more details

← Selinexor
reduces riskSelinexor
increases risk →

c19early.org

October 2026

Selinexor COVID-19 ICU results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Geils (SB RCT)−11%1.11 · 0.75–1.6333/6623/51XPORT-CoV-1001

Late treatment−11%1.11 · 0.75–1.6333/6623/5111% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.61

All studies−11%1.11 · 0.75–1.6333/6623/5111% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.6100.511.52+

Rotate screen for more detailsIncrease width for more details

← Selinexor
reduces riskSelinexor
increases risk →

c19early.org

October 2026

Selinexor COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Geils (SB RCT)−286%3.86 · 0.89–16.86death10/662/51XPORT-CoV-1001

Late treatment−286%3.86 · 0.89–16.8610/662/51286% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.072

All studies−286%3.86 · 0.89–16.8610/662/51286% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.07200.511.52+

Rotate screen for more detailsIncrease width for more details

← Selinexor
reduces riskSelinexor
increases risk →

c19early.org

October 2026

Selinexor COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Geils (SB RCT)−16%1.16 · 0.62–2.18no disch.18/6612/51XPORT-CoV-1001

Late treatment−16%1.16 · 0.62–2.1818/6612/5116% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.66

All studies−16%1.16 · 0.62–2.1818/6612/5116% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.6600.511.52+

Rotate screen for more detailsIncrease width for more details

← Selinexor
reduces riskSelinexor
increases risk →

c19early.org

October 2026

Selinexor COVID-19 viral clearance results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Geils (SB RCT)21%0.79 · 0.63–0.99viral+42/6641/51XPORT-CoV-1001

Late treatment21%0.79 · 0.63–0.9942/6641/5121% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.043

All studies21%0.79 · 0.63–0.9942/6641/5121% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.04300.511.52+

Rotate screen for more detailsIncrease width for more details

← Selinexor
reduces riskSelinexor
increases risk →

c19early.org

October 2026

Selinexor COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Geils (SB RCT)−286%3.86 · 0.89–16.86death10/662/51XPORT-CoV-1001

Late treatment−286%3.86 · 0.89–16.8610/662/51286% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.072

All studies−286%3.86 · 0.89–16.8610/662/51286% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.07200.511.52+

Rotate screen for more detailsIncrease width for more details

← Selinexor
reduces riskSelinexor
increases risk →

c19early.org

October 2026

Selinexor COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Geils (SB RCT)−286%3.86 · 0.89–16.8610/662/51XPORT-CoV-1001

Late treatment−286%3.86 · 0.89–16.8610/662/51286% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.072

All studies−286%3.86 · 0.89–16.8610/662/51286% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.07200.511.52+

Rotate screen for more detailsIncrease width for more details

← Selinexor
reduces riskSelinexor
increases risk →

c19early.org

October 2026

Selinexor COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Geils (SB RCT)−286%3.86 · 0.89–16.86death10/662/51XPORT-CoV-1001 Geils (SB RCT)−39%1.39 · 0.50–3.90ventilation9/665/51XPORT-CoV-1001 Geils (SB RCT)−11%1.11 · 0.75–1.63ICU33/6623/51XPORT-CoV-1001 Geils (SB RCT)−16%1.16 · 0.62–2.18no disch.18/6612/51XPORT-CoV-1001 Geils (SB RCT)−4%1.04 · 0.70–1.55no improv.31/6623/51XPORT-CoV-1001 Geils (SB RCT)21%0.79 · 0.63–0.99viral+42/6641/51XPORT-CoV-1001

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Selinexor
reduces riskSelinexor
increases risk →